Neogen Corporation

Neogen Corporation (NEOG) Market Cap

Neogen Corporation has a market capitalization of $2.07B.

Financials based on reported quarter end 2026-02-28

Price: $9.52

β–² 0.10 (1.06%)

Market Cap: 2.07B

NASDAQ Β· time unavailable

CEO: Mikhael Nassif

Sector: Healthcare

Industry: Medical - Diagnostics & Research

IPO Date: 1989-08-23

Website: https://www.neogen.com

Neogen Corporation (NEOG) - Company Information

Market Cap: 2.07B Β· Sector: Healthcare

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Analyst Sentiment

59%
Buy

Based on 11 ratings

Analyst 1Y Forecast: $9.50

Average target (based on 1 sources)

Consensus Price Target

Low

$10

Median

$11

High

$12

Average

$11

Potential Upside: 15.5%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ NEOGEN CORP (NEOG) β€” Investment Overview

🧩 Business Model Overview

Neogen Corporation (NEOG) operates as a global leader in food and animal safety solutions. The company develops, manufactures, and markets a comprehensive portfolio of products and services that serve diverse end-markets, including food processing, animal protein production, agribusiness, and life sciences. NEOGEN’s mission centers on food and animal safety, providing solutions that help detect, mitigate, and manage risks across global supply chains. The company’s strategy is anchored in innovation, expanding its product capabilities via both internal R&D efforts and strategic acquisitions. Its operations are organized into two principal reportable segments: Food Safety and Animal Safety.

πŸ’° Revenue Streams & Monetisation Model

NEOGEN’s revenue is derived primarily from the sale of diagnostic kits and consumables, complemented by instruments, software, and related services. The Food Safety segment generates revenue through platforms and tests used for detecting pathogens, toxins, drug residues, allergens, and sanitation indicators in food products and environments. Customers include food and beverage manufacturers, testing labs, and regulatory agencies. The Animal Safety segment caters to veterinarians, livestock producers, and companion animal markets, offering pharmaceutical products (e.g., vaccines, antibiotics), biosecurity solutions, veterinary instruments, and genetics testing. Subscription-based genomic testing and data services, as well as specialty chemicals and animal care solutions, create further recurring revenue streams. The business model emphasizes recurring consumable usage, underpinned by regulatory requirements and industry safety standards.

🧠 Competitive Advantages & Market Positioning

NEOGEN benefits from robust competitive moats through its established brand trust, broad and complementary product lines, and deep customer integration. Decades of R&D investment have resulted in a comprehensive diagnostic portfolio with high switching costs for customers, particularly due to validated platforms, regulatory compliance, and integration into customer workflows. NEOGEN’s global reach and supply chain capabilities, including strong distribution networks and localized manufacturing, further reinforce its position. The company’s strong relationships with major food producers and agricultural firms create embedded customer touchpoints that make displacement by competitors more challenging. Ongoing investments in digitalization and data analytics, particularly in genomic testing and livestock optimization, support a transition from pure diagnostics to broader data-driven decision-making platforms. NEOGEN faces competition from major multinational diagnostics and laboratory firms, but maintains defensible share in core niches via continual innovation, proprietary technology, and customer-centric service models.

πŸš€ Multi-Year Growth Drivers

Several secular and cyclical forces underpin NEOGEN’s long-term growth outlook: - **Rising Global Food Safety Standards**: Increasing regulatory requirements and consumer focus on foodborne risks drive demand for diagnostic solutions in developed and emerging markets. - **Protein Consumption Trends**: Growth in global protein consumption, particularly in developing economies, leads to expanded animal health testing and food safety protocols across supply chains. - **Advancement in Genomics and Precision Agriculture**: Adoption of genetic testing in livestock, as well as developments in precision agriculture, bolster demand for NEOGEN’s genomic services and data analytics platforms. - **Industry Consolidation & Geographic Expansion**: Strategic acquisitions have enabled NEOGEN to enter new verticals and geographies, complementing organic product innovation with inorganic growth. - **Biosecurity Awareness**: Increased attention to animal disease outbreaks, antimicrobial stewardship, and zoonotic disease risks highlight the need for robust animal safety and monitoring tools. - **Recurring Consumables Model**: High recurrence from diagnostic test kits, reagents, and animal care products creates consistent revenue flows, reducing cyclicality.

⚠ Risk Factors to Monitor

Key risks facing NEOGEN include: - **Regulatory Risk**: Changes in food and animal safety regulations, delays in product approvals, or increased scrutiny can impact product demand and compliance costs. - **Competitive Pressures**: Entrants with novel technologies or aggressive pricing can erode market share, especially if innovation cycles accelerate. - **Execution on M&A**: Challenges in integrating acquired businesses, realizing synergies, or managing cultural differences could affect financial performance. - **Currency & Geopolitical Risk**: As a company with significant international exposure, fluctuations in currency rates and geopolitical instability can impact results. - **Raw Material/Logistics Constraints**: Disruptions in supply chain logistics or input cost volatility could impair margins or product availability. - **Customer Concentration**: Reliance on large multinational food producers and animal health partners may expose NEOGEN to customer-driven volume or pricing risks.

πŸ“Š Valuation & Market View

NEOGEN is generally valued at a premium to broader industrial and diagnostic industry averages, in recognition of its defensive end-markets, innovation cadence, and high recurrence of consumable-driven revenues. The investment case is often framed around a combination of steady organic growth, margin expansion through scale and operational efficiency, and disciplined acquisitive activity. Market participants typically evaluate NEOGEN on metrics such as sales growth, recurring revenue ratio, EBITDA margins, and return on invested capital. Given the essential nature of its solutions and relative insulation from economic cycles, NEOGEN tends to retain support from quality and growth-oriented investors alike. However, valuation sensitivity to earnings execution and acquisition integration remains a notable consideration.

πŸ” Investment Takeaway

NEOGEN Corporation occupies a strong competitive position within the intersecting food and animal safety market. Its high-margin, recurring consumables-based revenue model, reinforced by secular regulatory and protein consumption trends, supports visibility and resilience. A strategic blend of innovation, digital transformation, and targeted M&A has enabled NEOGEN to diversify both geographically and by end-market. Forward risks include regulatory unpredictability, integration of acquisitions, and ongoing innovation requirements in the face of maturing core markets. For investors seeking exposure to enduring food safety and animal health trends, NEOGEN represents a compelling, albeit premium-valued, opportunity anchored in global supply chain safety and sustainability.

⚠ AI-generated β€” informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-02-28

"NEOG latest quarter (ended 2026-02-28) reported Revenue of $211.2m and Net Income of -$17.0m (EPS: -$0.08). QoQ revenue fell from $224.7m (down ~-6.0%), and losses widened slightly (net income down ~-6.7% vs. the prior quarter). YoY growth for this specific quarter was not computable from the provided dataset (no 2025-02-28 comparable quarter). Across the last four quarters, profitability was highly volatile: net margin swung from deeply negative (2025-05-31) to strongly positive (2025-08-31, ~+17.4% net margin), then back to losses (2025-11-30 and 2026-02-28, roughly -7% to -8% net margin). Operating cash flow remained positive ($10.9m–$22.7m), but FCF was inconsistentβ€”only the 2025-11-30 quarter showed positive FCF (+$43.4m), while the latest quarter was negative (~-$24.6m), indicating reliance on working-capital/capex timing. Balance sheet resilience improved: total assets were broadly stable (~$3.36b), equity was steady (~$2.10b), and net debt moved from positive ($647.6m) to net cash (~-$159.9m). Shareholder returns were strong: the stock is up ~74.4% over 1 year with no dividend, suggesting primarily capital appreciation (and possibly modest share reduction)."

Revenue Growth

Fair

QoQ revenue declined ~-6.0% (from $224.7m to $211.2m). YoY for the latest quarter could not be calculated because the comparable 2025-02-28 quarter is not included.

Profitability

Neutral

Net margin deteriorated to ~-8.0% in the latest quarter (from ~-7.1% QoQ). Over four quarters, earnings were extremely volatile: ~+17.4% net margin in 2025-08-31, then back to losses.

Cash Flow Quality

Caution

Operating cash flow stayed positive (~$10.9m–$22.7m), but FCF was unstable: latest quarter FCF ~-$24.6m and only 2025-11-30 was meaningfully positive (+$43.4m). No dividends and no clear buyback data provided.

Leverage & Balance Sheet

Good

Total assets and equity were broadly stable across the period (~$3.36b assets; ~ $2.10b equity). Net debt improved sharply from ~$647.6m (2025-11-30) to net cash ~$159.9m (2026-02-28).

Shareholder Returns

Strong

Total shareholder return is strongly supported by price momentum: 1y_change of ~+74.4% (>20% threshold). No dividend payments were reported.

Analyst Sentiment & Valuation

Neutral

Consensus price target (~$11) is below the current price context (~$9.42 indicates mismatch vs provided format; valuation is also distorted by negative earnings/PE). Negative EPS limits traditional valuation signals.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

So what: NEOG delivered solid Food Safety performance while Animal Safety was dominated by supplier-driven production and documentation problems rather than demand weakness. Q3 revenue was $211.2M (+0.1% core), with Food Safety at $156.7M (+4% core growth) driven by indicator/culture media (+11%) and pathogen test kit strength. Profitability improved meaningfully: adjusted EBITDA margin rose to 22.8%, up ~110 bps sequentially, despite lower revenue, reflecting disciplined cost control (9% sequential decline in adjusted operating expenses, though $1M was nonrecurring). However, margins were still pressured by sample-collection scrap from a third-party quality issue and Animal Safety backorders tied to: instrument manufacturer site transition/tariff mitigation, vitamin A shortages, and sodium bicarb partner production transition. Management raised FY26 revenue guidance to $857M-$860M but kept adjusted EBITDA at $175M, while explicitly flagging USD strength as a headwind beginning next quarter and expecting Animal Safety supplier challenges to persist into Q4.

AI IconGrowth Catalysts

  • Food Safety core growth of 4% (indicator testing and culture media products up 11%; pathogen test kits growing in bacteria and general sanitation)
  • Improving adjusted EBITDA margins via cost discipline (22.8% adjusted EBITDA margin, improved despite lower revenue)
  • Petrifilm manufacturing transition on track for planned November '26 transition; preparing to validate 17 SKUs (starting with highest volume/highest technical complexity)
  • Research scale R&D line at Minnesota facility starting in Q4 FY26 to prototype/validate new Petrifilm custom SKUs
  • Shift to global solutions-based selling model with metric-driven KPI tracking (weekly funnel metrics)

Business Development

  • 3M agreement extended/continued as an 'insurance policy' for Petrifilm-related disruption until August 2027
  • Investor tours: 2 upcoming investor tours at Lansing manufacturing facility in partnership with covering analysts

AI IconFinancial Highlights

  • Revenue: $211.2M, +0.1% on a core basis
  • Food Safety segment revenue: $156.7M (+4% core growth)
  • Animal Safety segment revenue: $54.5M; core revenue declined 8.7% YoY (supplier disruptions cited as driver); excluding impacts, Animal Safety would be more consistent with Q2
  • Gross margin: 46.9%; adjusted gross margin: 51.7%; YoY gross margins ex-onetime costs essentially flat
  • Adjusted EBITDA: $48.2M; 22.8% margin, improved ~110 bps sequentially from Q2 despite lower revenue (driven by adjusted operating expense decline of 9% sequentially; $1M of decline tied to nonrecurring credits)
  • Adjusted net income: $19.4M; adjusted EPS: $0.09
  • Freight/transportation costs headwind: high single-digit to low double-digit increases; ~$1.5M per quarter incremental freight/transportation impact
  • Iran/war exposure: revenue exposure to conflict-zone countries < $0.5M annually
  • Guidance raise: FY26 revenue to $857M-$860M
  • FY26 adjusted EBITDA guidance maintained at $175M

AI IconCapital Funding

  • Gross debt: $800M (68% fixed rate)
  • Cash balance: $159.9M
  • Free cash flow: $11.1M in Q3; positive for the year
  • Genomics divestiture: agreement to sell genomics business unit; sale price $160M; expected net proceeds ~$140M after transaction costs/taxes; close expected in Q2 FY27
  • Use of divestiture proceeds: reduce debt; net debt / adjusted EBITDA expected to decline to <3x by end of calendar 2026

AI IconStrategy & Ops

  • Operational efficiency transformation: advance/scale S&OP; complete transition of manufacturing operations; refine budgeting/forecasting
  • Petrifilm manufacturing transition: completed full validation of 100% of production equipment; initiated validation for current 17 SKUs (starting with highest volume/most technically challenging); aiming to complete product validations before commercial scale-up
  • Centralized planning model supported by AI-enabled logistics and supply chain software; expected operating model implementation by end of calendar year
  • Supplier management tightened: rigorous controls around cost/quality/performance; simplify warehousing/logistics footprint to reduce cost and operational complexity
  • Expense base disclosure: ~56% of operating expenses tied to salaries/benefits; expecting transformation-related spend to be excluded from adjusted financials (temporary foundation-building investment); longer-term spend positioned to decline; free cash flow expected to improve next year

AI IconMarket Outlook

  • FY26 revenue guidance raised to $857M-$860M
  • FY26 adjusted EBITDA guidance maintained at $175M
  • FX assumption: strengthening USD expected to diminish noncore currency tailwinds beginning next quarter; ~40% of revenue generated in non-U.S. dollar currencies
  • Q4 stance: more conservative view for Q4 due to continued Animal Safety supplier challenges; supplier-driven issues expected to continue into Q4 (no specific recovery number provided)

AI IconRisks & Headwinds

  • Animal Safety backorder disruptions driven by supplier issues (Q3): instrument supplier manufacturing relocation to reduce tariff impact (start-up challenges), global vitamin A shortage constraining several products, sodium bicarb partner transitioning production with issues
  • Supplier documentation/raw material shortages and delays tied to supplier manufacturing site transitions; compounded by supplier shifts driven by global tariff changes
  • Confidence limitation: company states issues are out of direct control but expects not to repeat in Q4; however, challenges expected to continue through Q4 as suppliers work through transitions
  • Sample collection margin headwind: higher scrap rates on certain sample collection products due to third-party supplier quality issue (now addressed); Q4 expected to improve sequentially
  • FX headwind from strengthening USD vs prior tailwinds; impacts reported growth starting next quarter
  • Macro/logistics: war-related cost pressure including rising fuel/fertilizer for customer margins; company cites freight/transportation cost increases (incremental ~$1.5M per quarter)
  • Guidance conservatism: Animal Safety supplier impacts plus FX tailwind reversal lead to cautious Q4 outlook

Sentiment: MIXED

Note: This summary was synthesized by AI from the NEOG Q3 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (NEOG)

Β© 2026 Stock Market Info β€” Neogen Corporation (NEOG) Financial Profile